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ABSTRACT 
Background: The emergence of drug resistance to P. falciparum becomes challenging. Thus, a continued 
search for other effective, safe and cheap plant-based antimalarial agents becomes imperative in the face of 
these difficulties.  
Objective: This study was aimed to investigate the antimalarial potentials of the crude stem bark extract and 
solvent fractions of P. linearifolia in Plasmodium berghei infected mice. 
Methods: The dried stem bark of P. linearifolia was pulverized and extracted with 80% methanol. The dried 
crude extract was then further fractionated with n-hexane, chloroform, and ethyl acetate. For suppressive test, 
after three hours post inoculation of P. berghei, the first group was administered the vehicle 10 ml/kg. The 
second group was given chloroquine 25 mg/kg. Whereas the remaining three groups were administered 200, 
400 and 600 mg/kg of the crude extract and 100,200 and 400 mg/kg of each of the chloroform, ethyl acetate 
and aqueous fractions. Furthermore, the crude extract and the aqueous fraction were evaluated using Rane’s 
model for the curative test.  The result was statistically analyzed using paired T-test and one-way analysis of 
variance (ANOVA). The results were considered significant at P < 0.05. 
Result: In the suppressive test, the crude extract and fractions suppressed parasitemia level significantly 
(P<0.05 for 200 and 400 mg/kg, P<0.001 for 600 mg/kg of the crude extract; P<0.01 for 100 mg/kg, P<0.001 
for 200 and 400 mg/kg of the aqueous and P<0.01 for 200 mg/kg, P<0.001 for 400 mg/kg of chloroform 
fractions). Whereas, in curative model 400 mg/kg of the aqueous fraction (P<0.01) and 600 mg/kg of the 
crude extract (P<0.001) showed a significant parasitemia level reduction. Both 400 and 600 mg/kg of the 
crude extract and 400 mg/kg of aqueous and chloroform fractions reversed reduction in packed cell volume.   
Conclusion: The results indicated that the plant is nontoxic at 2gm/kg and has a promising antiplasmodial 
activity against Plasmodium berghei, which upholds the earlier in vitro findings. Thus, it could be considered 
as a potential source to develop new antimalarial agents. 
Key Words: Antimalarial, Plasmodium berghei, Periploca linearifolia, parasitemia. 
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1. INTRODUCTION 
1.1. Overview of Malaria 
Malaria is one of the most common infectious diseases worldwide, particularly in Africa and south Asia. The 
number of malaria cases globally is about 212 million. More than 90% of the cases have occurred in the WHO 
African Region, followed by the WHO South-East Asia Region and the WHO Eastern Mediterranean Region. 
Globally, Plasmodium vivax accounts about 4% of estimated cases, but outside the African continent its 
infection proportion is 41% (1).  
On the other hand, the number of malaria deaths globally is around 429 000 of which 70% are children. More 
than 92% deaths were in the WHO African Region followed by the WHO South-East Asia Region and the 
WHO Eastern Mediterranean Region. Plasmodium falciparum malaria claimed the vast majority of deaths 
(99%) followed by P. vivax which was responsible for 3100 deaths, with 86% occurring outside Africa (1). 
Ignorance of the epidemiological diversity that characterizes Africa and the challenges it poses to sustained 
control and elimination will be the single largest threat to the global eradication agenda (2). 
Global financing for malaria control estimated to be US$ 2.9 billion in 2015. Of the total invested in the same 
year, international investments accounted for 68% and governments of malaria endemic countries for 32%  
(1). In Africa today, malaria becomes both a disease of poverty and a cause of poverty. Economists believe 
that malaria is responsible for a growth penalty of up to 1.3% per year in some African countries (3).  
1.2. Life Cycle of Plasmodium 
The natural ecology of malaria involves malaria parasites infecting successively humans and 
female Anopheles mosquitoes. In humans, the parasites grow and multiply first in the liver cells and then in 
the red cells of the blood. In the blood parasites grow inside the red cells and destroy them, releasing 
merozoites that continue the cycle by invading other red blood cells. The blood stage parasites are those that 
cause the symptoms of malaria. When gametocytes are picked up by a female Anopheles mosquito during a 
blood meal, they start another cycle of growth and multiplication in the mosquito (4). 
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Figure 1. Life cycle of the malaria parasite (4). 
During a blood meal, a malaria-infected female Anopheles mosquito inoculates sporozoites into the human 
host . Sporozoites infect liver cells  and mature into schizonts , which rupture and release merozoites . 
After this initial replication in the liver , the parasites undergo asexual multiplication in the erythrocytes . 
Merozoites infect red blood cells . Some parasites differentiate into sexual erythrocytic stages (gametocytes)
. The gametocytes are ingested by an Anopheles mosquito during a blood meal . The parasites’ 
multiplication in the mosquito is known as the sporogonic cycle . While in the mosquito's stomach, the 
microgametes penetrate the macrogametes generating zygotes . The zygotes in turn become motile and 
elongated (ookinetes)  which invade the midgut wall of the mosquito where they develop into oocysts . 
The oocysts grow, rupture, and release sporozoites , which make their way to the mosquito's salivary glands. 
Inoculation of the sporozoites  into a new human host perpetuates the malaria life cycle (4). 
1.3. Etiology and symptoms of malaria of Malaria  
Malaria in humans is caused by five species of parasites belonging to the genus Plasmodium. These include P. 
falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi (5, 6). Even though malaria parasites are 
commonly detected in blood donors, transfusion transmitted malaria occurs infrequently (7). 
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Symptoms of malaria are generally non-specific and most commonly consist of fever, malaise, weakness, 
nausea, vomiting, diarrhea, dizziness, confusion, disorientation, coma, headache, back pain, myalgia, chills 
and cough. On the other hand, malaria can be diagnosed with microscope, rapid diagnostic tests and 
polymerase chain reaction (PCR) (6, 8). 
1.4. Overview of Treatment of Malaria  
1.4.1. Antimalarial Drugs and Their Targets 
1.4.1.1. Cytosolic Targets 
Folate metabolism pathway is one of the drug targets in the cytosol. Unfortunately, resistance to individual 
dihydro folate reductase (DHFR) and dihydro pteroate synthase (DHPS) inhibitors, including pyrimethamine, 
proguanil and sulfas, leads to a marked loss in efficacy of even combination regimens (9). Similarly, 5- 
fluoroorotate exerts antimalarial activity via the inhibition of thymidylate synthase (10). 
Malaria parasites are dependent on glycolysis for energy production. P. falciparum lactate dehydrogenase’s 
unique binding site for the NADH cofactor offers opportunities for the design of selective inhibitors (11). 
Malaria parasites cannot synthesize purines and rely on salvage of host purines for nucleic acid synthesis. The 
principal source of purines in P. falciparum appears to be hypoxanthine, and hypoxanthine–guanine 
phosphoribosyltransferase (HGPRT) has been considered as a potential drug target (12).  
1.4.1.2. Parasite Membrane Targets 
The most abundant lipid in Plasmodial membranes is phosphatidylcholine. Synthesis of phosphatidylcholine 
requires host choline, and blockage of choline transport has been identified as a promising therapeutic strategy 
(13). A lead compound, G25 inhibited the development of cultured P. falciparum (14, 15).  
1.4.1.3. Food Vacuole Targets  
Antimalarial drugs appear to act by preventing hemozoin formation, producing free radicals in the food 
vacuole or, in the case of experimental compounds, preventing globin hydrolysis (16). Cysteine and aspartic 
parasite proteases (falcipains and plasmepsins, respectively) involved in the degradation of haemoglobin are 
also potential targets (17). 
The 4-aminoquinoline chloroquine appears to act by blocking the formation of hemozoin from heme 
molecules once they are liberated from hemoglobin (18). The food vacuole also appears to be the target of 
artemisinin antimalarials. Artemisinins contain an endoperoxide bridge that is essential for antimalarial 
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activity and that appears to undergo an iron-catalyzed decomposition into free radicals (19). The compounds 
apparently exert antimalarial effects via free radical damage, possibly by alkylation of Plasmodial proteins 
(20, 21).  
1.4.1.4. Mitochondrial Targets 
One antimalarial drug has a mitochondrial target. Atovaquone acts against ubiquinol–cytochrome c 
oxidoreductase (complex III), inhibits electron transport and collapses mitochondrial membrane potential, 
which is required for a number of parasite biochemical processes (22). 
1.4.1.5. Apicoplast Targets 
The apicoplast maintains certain specific functions, probably including fatty acid, heme and amino acid 
metabolism. Like the mitochondrion, the apicoplast has a separate, prokaryote-like genome, and this fact 
probably explains the antimalarial effects of a number of antibacterial compounds that otherwise do not attack 
eukaryotes (23). Many compounds probably act by targeting apicoplast and/or mitochondrial processes that 
are similar to those in bacteria (24). Tetracycline, clindamycin, macrolides and chloramphenicol inhibit 
different steps of prokaryote-like protein synthesis. Quinolone antibiotics inhibit DNA gyrase, and rifampin 
inhibits RNA polymerase, again with specificity to prokaryote-like activity (25). 
1.4.2. Treatment of Malaria 
The WHO recommended package of core interventions to prevent infection and reduce morbidity and 
mortality comprises vector control, chemoprevention, diagnostic testing and treatment (26). 
1.4.2.1. Uncomplicated Malaria 
P. falciparum or species not identified (acquired in areas without chloroquine resistance) 
For P. falciparum infections acquired in areas without chloroquine-resistant strains patients can be  treated 
with oral chloroquine (27, 28). 
P. falciparum or species not identified (acquired in areas with chloroquine resistance)  
For P. falciparum infections acquired in areas with chloroquine resistance, four treatment options are 
available. The first two treatment options are atovaquone-proguanil or artemether-lumefantrine, which can be 
used for adult and pediatric patients. Quinine sulfate plus doxycycline, tetracycline, or clindamycin is the next 
treatment option. The fourth option, mefloquine, is associated with rare but potentially severe 
neuropsychiatric reactions when used at treatment doses (27, 28). 
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P. malariae and P. knowlesi 
For both of these infections chloroquine may still be used. In addition, any of the regimens listed above for the 
treatment of chloroquine-resistant malaria may be used for the treatment of P. malariae and P. knowlesi 
infections (27, 28). 
P. vivax and P. ovale 
Chloroquine remains an effective choice for all P. vivax and P. ovale infections except for P. vivax infections 
acquired in Papua New Guinea or Indonesia. The regimens listed for the treatment of P. falciparum are also 
effective and may be used. The three treatment regimens for chloroquine-resistant P. vivax infections are 
quinine sulfate plus doxycycline or tetracycline, or, Atovaquone-proguanil, or mefloquine (27, 28). 
In addition to requiring blood stage treatment, infections with P. vivax and P. ovale can relapse due to 
hypnozoites that remain dormant in the liver. To eradicate the hypnozoites, patients should be treated with a 
14-day course of primaquine phosphate. For pediatric patients, the treatment options are the same as for adults 
except the drug dose is adjusted by patient weight (27, 28). 
Alternatives for Pregnant Women  
Malaria infection during pregnancy can lead to miscarriage, premature delivery, low birth weight, congenital 
infection and perinatal death. For pregnant women diagnosed with uncomplicated malaria caused by P. 
malariae, P. vivax, P. ovale, or chloroquine-sensitive P. falciparum infection, chloroquine is recommended. 
For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant P. falciparum 
infection, either mefloquine or a combination of quinine sulfate and clindamycin is recommended. For 
pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant P. vivax infection, 
mefloquine is recommended (27-29). 
For pregnant women diagnosed with uncomplicated malaria caused by chloroquine-resistant P. falciparum 
infection, atovaquone-proguanil or artemether-lumefantrine may be used if other treatment options are not 
available or are not being tolerated, and if the potential benefit is judged to outweigh the potential risks (28). 
1.4.2.2. Severe Malaria 
Patients who are considered to have manifestations of more severe disease should be treated aggressively by 
quinidine gluconate or parenteral artesunate. Once the parasite density is < 1% and the patient can take oral 
medication, the patient can complete the treatment course with an oral regimen such as oral quinine at the 
same dosage for uncomplicated malaria for a combined treatment course of quinidine/quinine. Other oral 
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regimens such as atovaquone-proguanil or artemether-lumefantrine may be used instead of an oral quinine 
based regimen (27, 28). 
1.5. Antimalarial Drug Resistance and Vector Resistance 
Currently, mosquitos become resistant to insecticides which jeopardizes malaria control. Therefore, failure to 
address the issue of insecticide resistance could undermine regional efforts to contain and eliminate 
artemisinin resistant parasites. The effectiveness of these interventions depends on the effectiveness of the 
insecticides used. Pyrethroids are currently the only insecticides available for treatment of mosquito nets (30). 
Antimalarial drug resistance is mediated by two processes. These are the rate that de novo mutations 
conferring resistance appear and are selected through drug use within an individual and the spread of those 
resistant alleles to other individuals. High mutation rates at the cellular level, which provide a means of 
continually evading the immune system, offer a mechanism for selection of resistance within a host, while 
interactions between other parasites and their hosts due to variation in transmission and host susceptibility and 
influence the probability of selection at the population level (31, 32). 
1.5.1. Drug resistance genetic markers 
Identification of potent drug-resistant molecular marker is an important tool to determine the emergence and 
spread of antimalarial drug resistance worldwide. Genetic crosslink and mapping studies of parasites assisted 
in identifying the genetic markers for drug resistance (33). Some of the genetic markers involved in drug 
resistance are listed below. 
1.5.1.1. P. falciparum Chloroquine Resistance Transporter (PfCRT) 
PfCRT protein belongs to the drug/metabolite transporter superfamily and chloroquine resistance transporter-
like transporter family with 10 putative transmembrane domain spanning the digestive vacuole membrane of 
the parasite (34). The K76T mutation in Pfcrt gene is the primary determinant of chloroquine resistance and 
susceptibility (35). Variation in the PfCRT protein influences antimalarial drug susceptibility and resistance to 
quinine, amodiaquine, piperaquine, and lumefantrine (36-39). 
1.5.1.2. P. falciparum Multidrug Resistance Protein 1 (PfMDR1) 
PfMDR1 protein is a transmembrane protein present in the digestive vacuole of the parasite similar to PfCRT 
protein and belongs to the ATP-binding cassette (ABC) superfamily (40, 41). Mutation in Pfmdr1 gene at the 
following position (N86Y, Y184F, S1034C, N1042D, and D1246Y) have been reported to involve in 
determining the drug susceptibility to chloroquine, quinine, mefloquine, halofantrine, lumefantrine, and 
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artemisinin (42-45). In addition, copy number variation of Pfmdr1 gene has been linked to higher level of 
resistance to quinine, mefloquine, halofantrine, lumefantrine, and artemisinin (46). 
1.5.1.3. P. falciparum Multidrug Resistance-associated Protein (MRP) 
MRP helps in the transport of organic anionic substrates such as oxidized glutathione, glucuronate, sulfate 
conjugates, and also in drug transport (47). Two mutations at position Y191H and A437S in PfMRP were 
found associated with CQ and quinine resistance (48). Thus, PfMRP is involved in varying the antimalarial 
response to resistance but not in determining the drug resistance mainly, and also hypothesized that PfMRP 
protein effluxes various metabolites and drugs out of the parasite in association with other transporters (49). 
1.5.1.4. Cytochrome B  
Cytochrome b (cytb) gene is a subunit of cytochrome bc1 complex, which catalyses the transfer of electrons 
across the inner mitochondrial membrane to maintain the electrochemical potential of the membrane (50).  
The antimalarial drug atovaquone binds to the ubiquinol binding site of cytb, thus disrupting the 
electrochemical potential of the mitochondrial membrane, which is fatal for the parasite survival (50). Single 
mutation at Y268N/S/C codon in the cytb gene associated with resistance to atovaquone in P. falciparum field 
isolates (42). 
1.5.1.5. Kelch 13 (K13 protein)  
The biochemical and cellular evidence showed that artemisinins are potent inhibitors of P. 
falciparumphosphatidylinositol-3-kinase (PfPI3K). In resistant clinical strains, increased PfPI3K was 
associated with the C580Y mutation in P. falciparum Kelch13 (PfKelch13), a primary marker of artemisinin 
resistance. The C-terminal region of K13 protein has six kelch motifs consisting of beta sheets that folded into 
a propeller domain and mutation in this region is predicted to disrupt the domain scaffold and alter its 
function. The kelch family proteins have diverse cellular functions, such as in organizing and interacting with 
other proteins (51, 52). Polyubiquitination of PfPI3K and its binding to PfKelch13 were reduced by the 
PfKelch13 mutation, which limited proteolysis of PfPI3K and thus increased levels of the kinase, as well as its 
lipid product phosphatidylinositol-3-phosphate (PI3P) (53, 54).  
1.6. Antimalarial Vaccine Development 
An ideal malaria vaccine requires three essential features: (i) multiple components that will induce an 
effective immune response to the different stages of the malaria infection; (ii) multiple epitopes that are 
restricted to presentation by different major histocompatibility complex (MHC) molecules; and (iii) 
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multiimmunogenicity inducing more than one type of immune response, including cell-mediated and 
humoral components (55-57). 
1.6.1. Transmission-Blocking Vaccines (TBVs) 
Transmission-blocking vaccines target antigens on gametes, zygotes and ookinetes to prevent parasite 
development in the mosquito midgut. The aim of these vaccines is to induce antibodies against the sexual-
stage antigens to block ookinete to oocyst transition to stop the subsequent generation of infectious 
sporozoites (58). One of the leading vaccine candidates in this group includes the P. falciparum ookinete 
surface antigens Pfs25 (59). 
1.6.2. Pre-erythrocytic vaccines 
The liver stage of P. falciparum is an attractive therapeutic target for the development of both antimalarial 
drugs and vaccines, as it provides an opportunity to interrupt the life cycle of the parasite at a critical early 
stage (60). To date, the most advanced pre-erythrocytic vaccine candidate is RTS,S/AS01, which consists of a 
truncated circumsporozoite protein (CSp) of P. falciparum directly fused to the hepatitis B surface antigen. A 
Phase 3 trial of RTS,S/ASO1 began in May 2009 and ended in early 2014, with 15 459 children in seven 
countries in sub-Saharan Africa (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania) 
(61). The WHO Regional Office for Africa (WHO/AFRO) announced on April 24, 2017, that Ghana, Kenya, 
and Malawi will collaborate with WHO in the Malaria Vaccine Implementation Programme (MVIP) that will 
make the RTS,S/ASO1 vaccine available in these three countries, beginning in 2018 (62).  A novel antigen, 
the cell-traversal protein for ookinetes and sporozoites (CelTOS), has been identified as an essential protein 
for the traversal of the malaria parasite in both mammalian and the insect hosts (63). 
1.6.3. Blood-stage vaccines 
From the several blood-stage antigens in clinical trials: apical membrane antigen 1 (AMA1) (64) and 
erythrocyte-binding antigen-175 (EBA-175) are some (65). The extensive genetic diversity of the parasite and 
the selective pressure exerted by the host’s immune response are major factors to be considered in the 
development of effective blood-stage vaccines (66).  
1.7. Herbal/Traditional Medicine as an Antimalarial Agent 
Traditional medicine (TM) is the oldest form of health care in the world and is used in the prevention, and 
treatment of physical and mental illnesses (67, 68). Such forms of medicine as traditional Chinese medicine 
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(TCM), Ayurveda, Kampo, traditional Korean medicine (TKM), and Unani employ natural products and have 
been practiced all over the world for hundreds or even thousands of years (69, 70). 
Through its use of natural products, TM plays a great role in the discovery of lead compounds and drug 
candidates. In TM, a single herb or formula may contain many phytochemical constituents, such as alkaloids, 
terpenoids, flavonoids, etc. Generally, these chemicals function alone or in conjunction with one another to 
produce the desired pharmacological effect (71, 72). 
Cinchona specious was traditionally used as an antimalarial remedy by the Incas in Peru. Quinine, the first 
antimalarial drug, is considered the prototype for the development of synthetic 4- and 8- aminoquinoline 
classes of antimalarial drugs, as exemplified by chloroquine and primaquine, respectively (73). 
The discovery of artemisinin can be traced back to the 1960s, when tropical malaria was a serious problem 
during the Vietnam War. North Vietnam requested China to help tackle the malaria problem. The Chinese 
government approved a project for malaria control and drug research in 1967. As part of the phytochemical 
and pharmacological research effort, a lot of Chinese herbal medicines were screened and investigated with 
respect to their toxicity or efficacy. Eventually artemisinin was derived from Artemisia annua L. in 1972 (74-
76). 
1.8. The experimental plant 
1.8.1 The Family-Asclepiadaceae 
Asclepiadaceae is a large family of 250 genera and over 2000 species: widespread in tropical and subtropical 
regions, especially in Africa and southern South America, with a moderate representation in northern and 
southeastern Asia. Members of this family are herbs, shrubs, or rarely treelike, with milky or, less often, clear 
latex (77, 78). 
1.8.2. The sub family Periplocoideae (Apocynaceae) 
It comprises 195 species belonging to 33 genera with most of the genera containing only a few species (79). 
Periploca was described by Linnaeus (1753) and is the type genus of the subfamily Periplocoideae (77, 79).  
From the plant species of Apocynaceae family in the Brazillian Amazon, Andrade Neto et al. isolated 
antiplasmodial indole alkaloids (80). The methanolic extracts from Carissa edulis (Apocynaceae) root bark 
were moderately active against the chloroquine sensitive strain of P. falciparum (81). 
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Both stem and leaf parts of Ochrosia akkeringae and Tabernaemontana pandacaqui (Apocynaceae) contain 
alkaloids and have potential antimalarial activity (81). Stem bark of ethanolic extract and chloroform fraction 
of Aspidosperma nitidum (Apocynaceae) showed a promising antimalarial activity (82).  
Aspidosperma olivaceum (Apocynaceae), which is used to treat fevers in some regions of Brazil, contains the 
monoterpenoid indole alkaloids aspidoscarpine, uleine, apparicine, and N-methyl-tetrahydrolivacine which 
are active in vitro against erythrocytic stages of P. falciparum (83). 
Cryptolepis sanguinolenta Lindl. Schltr. (Periplocaceae) is used for the treatment of fevers. It is used for 
urinary tract infections, especially Candida, inflammatory conditions, malaria, hypertension, microbial 
infections and inflammatory conditions, stomach aches colic (84). Active principals identified are indole 
quinoline alkaloids (85). 
1.8.2. The genus Periploca 
Many chemical compounds have been isolated and identified from species of the Periploca genus, such as α- 
and β-amyrin, lupeol and β-sitosterol from Periploca laevigata (86). Moreover, several lupene-type 
triterpenes and elemane-type sesquiterpenes have been isolated from Periploca aphylla and roots of P. 
laevigata respectively (86, 87). Lupeol, β-amyrin and β-sitosterol (terpenoids) inhibited both chloroquine 
sensitive and resistant strains of P. falciparum (88). 
1.8.3 Periploca linearifolia Quart.-Dill. & A.Rich. (Asclepiadaceae) 
P. linearifolia (also known as “Moyder” in Amharic) is a liana, woody at base, up to 10 m long, glabrous and 
latex copious. Leaves are opposite, simple and entire, almost sessile; stipules are absent. Flowers are bisexual; 
pedicle is 5-10 mm long; sepals are ovate; whereas lobes are slightly fleshy and glandular, spreading oblong-
ovate. Fruit comprises a pair of follicles, which are horizontal. Each follicle is linear-ovoid, which are many 
seeded. Seeds are ovate, brown, tuft of hairs white. The plant occurs in eastern Central Africa, East Africa and 
part of southern Africa, from Ethiopia south to eastern DR Congo, Malawi and Zimbabwe (89). 
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Figure 2. Morphological view of Periploca linearifolia Quart.-Dill. & A.Rich.  
1.8.4. Reported Ethnobotanical Use and in vitro studies P. linearifolia 
Hot water decoction of root bark of P. linearfolia is used as antimalarial in Meru district, Kenya (90). Leaves 
are macerated in water and used as a dressing to treat mastitis. A leaf decoction is drunk to treat diarrhea, 
intestinal worms and insanity. The leaf sap in water or a root decoction is taken by pregnant women as a tonic 
and to stop vomiting. Pounded leaves in water are taken to treat female sterility (89).  
A root bark infusion or decoction is drunk or applied as enema to treat tapeworm and other intestinal worms. 
Roots cooked in soup are eaten to treat fever, malaria, chest complaints, including cough and pneumonia, 
female infertility and venereal diseases. Root powder and latex is externally applied to hemorrhoids. The 
leaves and fruits of P. linearifolia are used for the eradication of lice in goats and sheep (89, 91). 
An in vitro antimalarial test with a methanolic stem bark extract of P. linearifolia showed highly significant 
antiplasmodial activity in vitro against a chloroquine sensitive and resistant strain of P. falciparum. In 
addition, a chloroform stem bark extract showed a moderate antiplasmodial activity in vitro against a 
chloroquine sensitive strain. The extracts showed low toxicity in a brine shrimp cytotoxicity assay. A 
methanolic extract of the leafy stem showed significant antibacterial activity and moderate antifungal activity 
in vitro (88, 89, 92).  
Three compounds namely Lupeol, β- sitosterol and β- amyrin which were isolated from the root bark of P. 
linearifolia found to inhibit both chloroquine sensitive and resistant strains of P. falciparum (88).  
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1.8.5. Phytochemical constituents of P. linearifolia Quart.-Dill. & A.Rich.  
The leaf extracts from P. linearifolia contain phytin, anthraquinone, gemnamagenin, gymnemic acid II, 
betaine, cholin and lupeol (93, 94). Three terpenoids namely, Lupeol, β- sitosterol and β- amyrin were isolated 
from the root bark of P. linearifolia (88). 
1.9. Justification of the Study 
Due to the pandemic nature and fatality of malaria and the emergence of antimalarial drug resistance, 
especially to chloroquine and artemisinin derivatives, there is a high interest of developing new and affordable 
antimalarial drugs. To mention some of the challenges, the most important one is Plasmodium parasites are 
resistant to the most widely available, affordable and safest antimalarial drugs. Moreover, currently available 
indoor spraying with insecticides to reduce the transmission of malaria is hampered by insecticide resistance 
(1, 95). Indeed, artemisinin resistance to a deadly P. falciparum now poses a threat to the control and 
elimination of malaria. Chloroquine resistant strains can be controlled by artemisinin and artemisinin 
derivatives. But, currently there is no alternative approved antimalarial drug to replace artemisinin derivatives. 
Hence, it is extremely important to urgently intensify research in the development of new, cheap and effective 
antimalarial drugs. Medicinal plants remain the main focus by scientists as a noble source of new lead 
compounds in the development of new antimalarial agents.  
Hence, Ethiopia, with a wealth of natural resources, is an ideal place to search for new drugs from plants. The 
finding of this experimental study helps the scientific community to further investigate on the plant, P. 
linearifolia, by initiating advanced studies on formulation and molecular mechanisms of plant source drugs 
and by identifying and isolating a specific antimalarial compound. Unless such types of screening studies are 
carried out and potential new antimalarial drugs discovered, the drug resistance phenomenon may lead us to 
the pre-antibiotic/antimicrobial era. Ethiopia being rich in flora which can be sources of different new 
antimalarial agents, further screening of plants is important.  
An in vitro antimalarial test with a methanolic and chloroform extract of the stem bark of P. linearifolia 
conducted in Kenya, showed a promising antiplasmodial activity against a chloroquine sensitive and resistant 
strains. This plant is used for the treatment of malaria in the Lake Victoria region and Meru district, Kenya 
(92). Therefore, the present study describes the in-vivo antimalarial activity of crude extract and solvent 
fraction of P. linearifolia in mice infected with chloroquine sensitive P. berghei. 
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2- OBJECTIVES 
2.1. General Objective 
 To evaluate the antimalarial activity of crude extract and solvent fractions of the stem bark of 
Periploca linearifolia Quart.-Dill. & A.Rich. (Asclepiadaceae) against Plasmodium berghei in 
mice. 
2.2. Specific Objectives 
 To carry out preliminary phytochemical screening of the crude hydroalcoholic extract of P. 
linearifolia;  
 To determine the acute oral toxicity of the hydroalcoholic extract of P. linearifolia;  
 To evaluate the in vivo antimalarial activity of the hydroalcoholic extract of P. linearifolia;   
 To evaluate the in vivo antimalarial activity of the solvent fractions 
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3. METHODS 
3.1. Drugs and Chemicals  
Normal isotonic saline (Euro-med Laboratories, Phillippines), absolute methanol (ReAgent chemical services, 
UK), n-hexane, 2% tween 80, hydrochloric acid (Blulux laboratories, India ), ethyl acetate (Loba chemicals, 
India), chloroform (Atico, India), citrate dextrose (Deluxie Scientific Surgico, India), giemsa (Science Lab, 
USA), ethanol (Nice chemicals, India), ferric chloride (Fisher Scientific CO, USA), sodium hydroxide 
sulfuric acid (Supertech, India) and Mayer’s reagent (Avishkar Lab Tech Chemicals, India) were used.  
3.2. Materials 
 Electrical balance, 1 ml syringes (Hindustan, India), needles Shandong Zibo, China), vials, examination 
glove, permanent marker, Whatman filters paper No.1 (Whatman ®, England) , collecting flask, separatory 
fennel, hematocrit centrifuge, Micro-Hematocrit Reader (Hettich, Germany), microscope (Olympus, Japan) 
and laboratory glass wares were used. 
3.3. Plant Material 
Stem bark of P. linearifolia plant was collected from Lay Armachiho Woreda, near Tikil Dingay town, North 
Gondar Zone, 23 kms North of Gondar city on December, 2016. The collected plant material was wrapped 
with plastic sheets during transportation. The plant was identified as Periploca linearifolia Quart.-Dill. & 
A.Rich. by Mr. Abiyu Enyew (botanist) and a voucher specimen was deposited (No. WY001) at the 
Herbarium of biology department, University of Gondar for future reference. 
3.4. Experimental Animals 
Healthy, adult Swiss albino mice of either sex (22-32 g, and 6–8 weeks of age) were obtained from the animal 
house of the School of Pharmacy, College of Medicine and Health Science (CMHS), University of Gondar 
(UoG). The animals were housed in cages under standard conditions and provided with pellet diet and water 
ad libitum. The animals were allowed to acclimatize to the laboratory condition for a week before beginning 
the experiment. All protocols were performed based on the international animal care and welfare guidelines 
(96). The study protocol was approved by the ethical review board of Department of Pharmacology, School of 
Pharmacy, UoG. The experiment was conducted following approval by the above body for the use of animals 
for experiment. 
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3.5. Parasite 
Chloroquine sensitive strain of P. berghei (ANKA strain) obtained from the Ethiopian Public Health Institute, 
Addis Ababa was used. The parasites were maintained by serial passage of blood from infected mice to non-
infected ones on weekly basis. 
3.6. Extract preparation 
The stem bark was peeled from the plant, air dried at room temperature under shade and reduced to 
appropriate size. A total of 1.2 kg dried stem bark was extracted by maceration (100 g of dried stem bark in 
600 ml of 80% methanol) for 72 h. The mixture was first filtered using gauze and then with Whatman filters 
paper No. 1 (Whatman ®, England). The residue was re-macerated for another 72 hour twice and filtered. The 
combined filtrates were then put under oven at a temperature not more than 40°C. After evaporating methanol 
and some part of the aqueous part, it was transferred to a desiccator for further drying. The dried extract was 
kept in a vial and stored in a refrigerator at −4°C until use (97).  
3.7. Preparation of fraction   
The crude 80% methanolic extract was dissolved in distilled water and successively partitioned using different 
solvents of increasing polarity (n-hexane, chloroform, and ethyl acetate) in a separatory funnel as shown 
schematically in Figure 3. The different solvent fractions were concentrated and dried in oven under 40 0C. 
The aqueous fraction was dried by lyophilizer. The dried fractions were then transferred into separate vials 
and stored in a refrigerator at −4°C for further use. 
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Figure 3. Schematic diagram for extraction and fractionation of the stem bark of P. linearifolia 
3.8. Preliminary Phytochemical Screening 
The 80% methanolic extract of P. linearifolia stem bark was screened for the presence of secondary 
metabolites to relate the antimalarial activity of the plant with the presence or absence of these constituents. 
Thus the tests for alkaloids, saponins, flavonoids, terpenoids, phenols and tannins were performed according 
to standard tests as described below. 
Test for Alkaloids  
Crude extract was mixed with 2 ml of 1% hydrochloric acid (HCl) and heated gently. Mayer’s and/or 
Wagner’s reagents were then added to the mixture. Presence of alkaloid was confirmed by turbidity of the 
resulting precipitate (98). 
 
 
Powdered stem bark of P. linearifolia (1.2 kg) 
80% Methanol (3 days x 3) 
Crude (80%MeOH) extract                    Residue 
n - Hexane (x 3) 
 
n-Hexane fraction Residue 
Chloroform (x 3) 
Chloroform fraction Residue 
Ethyl acetate (x 3) 
Ethyl acetate fraction Aqueous fraction 
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Tannins test (Braymer’s Test)  
2 ml of extract was mixed and then treated with 2-3 drops of ferric chloride (5%) and formation of green 
precipitate was used as indication of presence of tannins (99). 
Test for terpenoids 
Crude extract was dissolved in 2 ml of chloroform and evaporated to dryness. To this, 2 ml of concentrated 
sulfuric acid (H2SO4) was added and heated for about 2 minutes. Formation of grayish color indicated the 
presence of terpenoids (99). 
Test for flavonoids (Alkaline reagent test)  
Crude extract was mixed with 2 ml of 2% solution of sodium hydroxide solution. The formation of intense 
yellow color which becomes colorless upon the addition of a few drops of diluted H2SO4 showed the presence 
of flavonoids (99). 
Test for saponins (foam test)  
Crude extract was mixed with 5 ml of distilled water in a test tube and it was shaken vigorously and stable 
foam formation was taken as an indication for the presence of saponins (98). 
Test for phenols (Ferric chloride test)  
A fraction of the extract was treated with aqueous 5% ferric chloride and was observed for formation of deep 
blue or black color which indicated presence of phenols (100). 
3.9. Acute Oral Toxicity Study 
Acute toxicity testing was conducted for the 80% methanol extract (single dose 2 g/kg) using Organization for 
Economic Cooperation and Development guidelines.  The extract was evaluated for its toxicity in non-
infected female Swiss albino mice aged of 6-8 weeks and weighing 26-32 g. The mice were fasted for three 
hours and weighted before test. A single female mouse was given 2 g/kg of the extract as a single dose by oral 
gavage. After administration of the extracts food was withheld for further two hours period. The mice was 
strictly followed for four hours and then for 24 hours. Since, death was not recorded in the first 24 hrs, another 
4 female mice were given the same dose based on the outcome of the first animal. The animals were observed 
for toxicities like diarrhea, weight loss, absence of tremor, lethargy and paralysis periodically for the first four 
hours during the 24 h period and later were followed for 14 days for any adverse effect and lethality (96). 
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3.10. In vivo Antimalarial Activity Testing 
P. berghei (ANKA strain) was used for induction of malaria in experimental mice. The parasites were 
maintained by intraperitoneal serial passage of blood. The infected blood was then collected in test tubes by 
decapitation and diluted with isotonic saline before it was given to the different groups of mice.  
3.10.1. Suppressive test 
3.10.1.1. Antimalarial activity test of the crude extract 
The standard four-day suppressive test method was used (97, 101). Blood was taken from a donor mouse with 
approximately 20%-30% parasitemia and diluted in physiological saline to 5 x 107 parasitized erythrocytes 
per ml. Swiss albino mice weighing 22-32 g were infected with 0.2 ml (1 x 107 parasitized erythrocytes) P. 
berghei intraperitoneally (i.p.) and were randomly divided into five groups of five mice with three test groups 
and two control groups (each for chloroquine as a standard drug and distilled water as a negative control) (97). 
The test extract was prepared in three different doses (200, 400 and 600 mg/kg) and chloroquine at 25 mg/kg. 
Each vehicle, extract or chloroquine were administered as a single dose daily. The extracts and the drug were 
given through oral route by using standard oral gavage. The dose levels of the extracts and fractions were 
selected for mice based on the result obtained from the oral acute toxicity test.  
Treatment was started 3 hour post infection on day 0 and continued daily for four days (i.e. from day 0 to day 
3). On the fifth day (D4) thin smears of blood films were obtained from the peripheral blood on the tail from 
each mouse. The smears were placed on microscopic slides which were fixed with methanol and stained with 
10% giemsa at pH 7.2 for 15 min. The parasitemia level was determined by counting the number of 
parasitized erythrocytes out of four random fields of the microscope. Average percent parasitaemia and 
suppression was calculated by using the following formula (97, 101). 
% Parasitemia =  
Number of parasitized RBC       
Total number of RBC
  x 100  
% suppression =  
mean parasitemia of negative control − mean parasitemia of treated group
mean parasitemia of negative control
 x 100 
3.10.1.2. Antimalarial activity test of fractions 
Chloroform, ethyl acetate and aqueous fractions of the crude extract were administered with three different 
doses for each 100, 200 and 400 mg/kg orally daily to respective groups of five mice each 3 h post-infection 
intraperitoneally with 0.2 ml of infected blood containing about 1 x 107 P. berghei. A negative control group 
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was administered the 2% Tween 80 while chloroquine (25 mg/kg/day) was given to the positive control 
group. The administration was continued for four days. On the fifth day, thin films were prepared from tail 
blood of each mouse and the parasitemia levels were determined by counting the number of parasitized 
erythrocytes in four random fields of the microscope. The average percentage chemosuppression was 
calculated as shown under section 3.2.5.1.1 (97, 101).  
3.10.2. Rane’s Test  
Evaluation of the curative potential of the crude extract and the aqueous fraction (the most active fraction in 
the four day suppressive test) were carried out according to the method described by Ryley and Peters (102). 
On Day 0, standard inocula of 1 × 107 infected erythrocytes were inoculated in mice intraperitoneally. 
Seventy-two hours later, mice were randomly divided into eight groups of five mice. The first three groups 
belonged to 200, 400 and 600 mg/kg of the crude extract and the other three groups were assigned for 100, 
200 and 400 mg/kg of the aqueous fraction. Whereas the remaining two groups belonged for the vehicle 
distilled water 10 ml/kg and chloroquine 25 mg/kg.  
All mice were dosed, as described in the four day suppressive test, orally once daily for four days. Geimsa 
stained thin blood film were prepared from the tail of each mouse daily for 5 days from day three to day seven 
to monitor parasitemia level. The average percentage parasitemia was calculated as shown under section 
3.2.5.1.1. Mean survival time (MST) for each group was determined arithmetically by calculating the average 
survival time (days) of mice starting from date of infection over a period of 30 days (D0-D29). 
MST =  
Sum of survival time of all mice in group (days)
Total number of mice in that group
 
3.10.3. Packed Cell Volume Measurement 
Packed cell volume (PCV) was measured to predict the effectiveness of the test extract and solvent fractions 
in preventing hemolysis resulting from increasing parasitemia associated with malaria. Heparinized capillary 
tubes were used for collection of blood from tail of each mouse. The capillary tubes were filled with blood up 
to ¾th of their volume and were sealed at the dry end with sealing clay. The tubes were then placed in a micro-
hematocrit centrifuge, with the sealed end outwards and was centrifuged for 5 min at 11,000 rpm. The tubes 
were then taken out of the centrifuge and PCV was determined using a standard Micro-Hematocrit Reader. 
PCV is a measure of the proportion of RBCs to plasma and measured before inoculating the parasite and at 
day four using the following relationship: 
PCV =  
Volume of erythrocytes in a given volume of blood
Total blood volume
 x 100% 
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3.10.4. Monitoring of Body Weight and Temperature Changes 
For a four day suppressive test and Rane’s test, the body weights of the mice were determined to observe 
whether the stem bark extract or solvent fractions prevented weight loss. Weights were taken on day zero 
(D0) and day five (D4). Rectal temperature was measured by a digital thermometer before infection, four 
hours after infection and then daily. For Rane’s test, body weight and temperature were measured before 
infection and from day 3–7 after infection.  
3.10.5. Statistical Analysis 
 The raw datas obtained from the experiments were expressed as mean ± SEM (standard error of the mean). 
Statistical analyses were carried out by using SPSS Statistical software version 20. All the parametrs 
parasitemia level, % suppresson, mean survival time, PCV, temperature and weight were statistically analyzed 
using one-way  analysis of variance (ANOVA) followed by post hoc Tukey’s Multiple Comparison Test. 
PCV, temperature and weight were statistically analyzed using paired T- test to analyze the difference within 
groups before and after treatment. The results were considered significantly different when p < 0.05. 
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4. RESULT  
4.1. Percentage yields of crude extract and fractions 
From the 80% methanolic extract of stem bark of P. linearifolia a total of 151 g (12.6% yield) of brownish 
colored dry extract was harvested. While the n- hexane (0.15%) and the chloroform (2.85%) fractions were 
found to be greenish whereas, the dark reddish for ethyl acetate (4%) and reddish color for aqueous fraction 
(93%) were found. n-Hexane fraction was not considered in the experiment due to insufficient quantity.  
4.2. Preliminary Phytochemical screening 
Phytochemical screening of the hydroalcoholic crude extract of stem bark of P. linearifolia revealed the 
presence of alkaloids, saponins, phenolic compounds, tannins and terpenoids. Whereas, flavonoids were 
absent from the crude extract.  
Table 1. Preliminary phytochemical screening of the crude hydroalcoholic extract of P. linearifolia 
Phytochemical Result 
Alkaloids + 
Saponins + 
Flavonoids - 
Terpenoids + 
Phenols + 
Tannins + 
+ = present;                          - = absent 
4.3. Acute oral toxicity study  
The acute oral toxicity study indicated that the extract caused no mortality in 2 g/kg single dose within the 
first 24 hour as well as for the following 14 days. Physical and behavioral observations of the experimental 
mice also revealed no visible signs of toxicity like lacrimation, loss of appetite, tremors, hair erection, 
salivation, diarrhea and the like. This suggests that the oral LD50 of the extract is greater than 2 g/kg. 
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4.4. Antimalarial activity  
4.4.1. Four day suppressive test of the crude extract   
The results of the study showed that the crude extract of P. linearifolia displayed a statistically significant 
parasitemia level reduction dose dependently compared to vehicle treated mice (p<0.05 for 200 and 400 
mg/kg; p<0.001 for 600 mg/kg) (Table 2). In addition, percentage inhibition analysis indicated that the extract 
produced a dose-dependent chemosuppression. Moreover, 600 mg/kg was capable of significantly increasing 
survival time (p<0.05) compared to vehicle treated mice, but the effect was significantly lower than the 
standard drug chloroquine 25 mg/kg (p<0.001). 
4.4.2. Four day suppressive test of the solvent fractions 
All the three doses of aqueous fraction dose-dependently reduced parasitemia level compared to vehicle 
treated group (p<0.01 for 100; p<0.001 for 200 and 400 mg/kg), although the extent of reduction was less 
than that of chloroquine 25 mg/kg, which produced 100% suppression (Table 2). The two higher doses of the 
chloroform fraction (200 and 400 mg/kg) dose-dependently reduced parasitemia level compared to vehicle 
treated group (p< 0.01 for 200 mg/kg; p<0.001 for 400 mg/kg). However, only 400 mg/kg of ethyl acetate 
fraction reduced parasitemia level significantly (p<0.05). The rank order of chemosuppression of the solvent 
fractions was aqueous (53.4%) > chloroform (41.11%) > ethyl acetate (35.51%), at the dose of 400 mg/kg. 
Survival date was significantly prolonged by 400 mg/kg of all the fractions as compared to vehicle treated 
mice (p<0.05) (Table 2).  
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Table 2. Parasitemia level and survival time of infected mice treated with crude extract and solvent fractions 
of P. linearifolia in the 4 day suppressive test 
 
Extract/Fraction 
 
Dose 
 
 
Parasitaemia level 
 
% suppression 
 
Survival time 
Crude extract of    
P. linearifolia 
200 mg/kg 24.57±3.29a1,b3 38.17±8.28 8.60±0.67 
400 mg/kg 22.52±3.40a1,b2 43.33±8.56 11.60±2.56 
600 mg/kg 17.10±2.88a3,b1 56.98±7.25 16.4±4.20a1,b 2 
Distilled water 10 ml/kg 39.74±4.99       - 6.80±0.37 
Aqueous fraction 
 
100 mg/kg 25.29±3.23a2,b3 39.06±7.78 8.40±0.5b3 
200 mg/kg 22.69±3.22a3,b3 45.37±7.75 9.80±1.06b3 
400 mg/kg 19.34±2.13a3,b3 53.40±5.14 15.80±3.92a1,b3 
Ethyl acetate fraction 
 
100 mg/kg 34.87±3.94b3 15.99±9.49 8.40±0.74b 3 
200 mg/kg 33.72±4.40b3 20.70±9.40 10.40±0.92b3 
400 mg/kg 26.77±2.29a1,b3 35.51±5.53 10.80±1.39a1, b 3 
Chloroform fraction 
 
 
100 mg/kg 31.24±2.57b3 24.74±6.20 8.40±1.14b3 
200 mg/kg 26.98±3.01a2,b3 35.00±7.26 10.00±1.58b 3 
400 mg/kg 24.44±2.89a3,b3 41.11±6.96 14.00±5.00a2,b3,c1 
2% Tween 80 10 ml/kg 41.52±2.81           - 7.00±0.31 
Chloroquine 25 mg/kg 0.00±0.00a3 100.00±0.00 30.00±0.00a3 
Data are expressed as mean ± SEM; n = 5; a, compared to vehicle (Distilled water for crude extract and 2%Tween 80 
10ml/kg for fractions); b to chloroquine 25 mg/kg; c to chloroform fraction 100 mg/kg: 1p<0.05, 2p<0.01, 3p<0.001. 
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4.4.3. Effect of crude extract and solvent fractions on rectal temperature and body weight on the four 
day suppressive test 
Analysis of the rectal temperature revealed that 600 mg/kg of crude extract caused a statistically significant 
attenuation of reduction in temperature of P. berghei infected mice (p<0.05), but it was lower than 
chloroquine 25 mg/kg (p<0.001). All doses of the crude extract failed to prevent the reduction in body weight 
significantly; but the standard drug chloroquine 25 mg/kg averted it significantly (p<0.001) (Table 3).  
Analysis of rectal temperature within groups showed that groups of mice treated with 200 mg/kg of the crude 
extract did not show any significant temperature change after treatment. Similarly the standard drug 
chloroquine 25 mg/kg prevented significant temperature reduction. But other doses did not show any 
significant prevention of the reduction in rectal temperature. Also analysis of body weight indicated that mice 
administered with the standard drug chloroquine 25 mg/kg did not show any significant weight change after 
treatment. All doses of the crude extract failed to prevent a significant weight change after treatment.   
All doses of the fractions, except 400 mg/kg chloroform extract failed to prevent body weight reduction 
significantly. But, 400 mg/kg of chloroform showed a significant attenuation of body weight reduction 
(p<0.05). On the other hand, the standard drug chloroquine 25 mg/kg significantly prevented body weight 
reduction (p<0.01) (Table 3). Moreover, all doses of the aqueous fraction significantly (p<0.001) prevented 
the rectal temperature reduction caused by escalating parasitemia and the effect was comparable to that 
observed with chloroquine 25 mg/kg. Similarly, all doses of chloroform fraction (p<0.01), 200 and 400 mg/kg 
of ethyl acetate fraction (p<0.05) significantly prevented rectal temperature reduction (Table 3). 
Analysis of rectal temperature change within groups indicated that mice administered with 100 mg/kg and 400 
mg/kg of the aqueous fraction did not show any significant temperature change after treatment.  In addition, 
chloroquine 25 mg/kg prevented a significant rectal temperature change. But ethyl acetate and chloroform 
fractions did not show any significant prevention of temperature change. On the other hand there was no 
significant weight change after treatment by group of mice treated with chloroquine 25 mg/kg. No dose of all 
the three fractions prevent weight reduction significantly.  
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Table 3 Rectal temperature and body weight change of infected animals treated with crude extract and solvent 
fractions of P. linearifolia in the 4 day suppressive test. 
                                       
Extract/ 
Fraction 
 
 
Dose 
     
Temperature (℃) 
 
Weight  
     
 D0 
     
 D4 
 
% Change 
  
 D0 
 
D4 
 
% change 
Crude extract 
of  
P. 
linearifolia 
200 37.18±0.32 36.46±0.2 -1.93 28.8±1.11 26.74±0.92 -7.15 
400 37.68±0.05 37.04±0.16 -1.69 27.72±1.00 25.76±1.20 -7.07 
600  37.58±0.09 37.20±0.11 -1.01a1 26.9±1.23 24.92±1.38 -7.36 
D/water 10 36.76±0.22 35.16±0.29 -4.35 30.42±0.72 26.56±0.89 -12.68 
Chloroquine 25 36.76±0.33 36.9±0.24 0.38a3 27.52±1.70 27.38±1.42 -0.50a2 
Aqueous 
fraction 
 
100 37.22±0.08 36.84±0.12 -1.02a3 25.78±1.07 22.40±1.27 -13.11b2 
200 37.52±0.23 37.18±0.18 -0.90a3 27.46±1.55 24.46±1.76 -10.92b2 
 400 37.48±0.08 37.42±0.07 -0.16a3 26.54±1.27 23.9±1.49 -9.94b2 
Ethyl acetate  
Fraction 
100  37.06±0.12 35.90±0.17 -3.13 27.56±1.16 24.38±1.13 -11.53b2 
200  37.42±0.10 36.62±0.24 -2.13a1 25.42±0.98 23.26±0.81 -8.49b1 
400 37.14±0.10 36.72±0.19 -1.13a2 27.20±1.06 24.80±1.39 -8.82b1 
Chloroform  
Fraction 
100 37.3±0.16 36.70±0.15 -1.60a2 28.06±1.41 24.92±1.49 -11.19b3 
200 37.82±0.09 37.06±0.13 -2.02a2 27.66±1.20 25.00±1.14 -9.59b2 
400 37.5±0.07 37.06±0.12 -1.17a2 27.72±1.24 25.74±1.16 -7.14a1,b1 
2%Tween80 10 37.76±0.23 36.12±0.30 -4.34 29.38±0.91 25.04±0.99 -14.77 
Chloroquine 25 37.08±0.22 36.94±0.16 -0.37a3 26.66±1.34 26.56±1.34 -0.37a2 
Data are expressed as mean ± SEM; n = 5; a = compared to vehicle (Distilled water for crude extract and 2%Tween 80 
10ml/kg for fractions); b to CQ: 1p< 0.05; 2p<0.01, 3p<0.001; D0 = pre-treatment value on day 0, D4 = post-treatment 
value on day four, Numbers refer to dose in mg/kg. 
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4.4.4. Effect of crude extract and solvent fractions on packed cell volume (PCV) on the four day 
suppressive test 
Both 400 and 600 mg/kg of the crude extract significantly prevented the reduction (p<0.05 for 400 mg/kg and 
p<0.01 for 600 mg/kg) as compared to vehicle treated mice. However, the effect was lower than chloroquine 
25 mg/kg (p<0.001). Moreover, within group analysis of PCV indicated that neither the standard drug nor the 
crude extract prevented any significant PCV change after treatment (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Packed cell volume of infected animals treated with crude extract of P. linearifolia in the 4 day suppressive 
test. Data are expressed as mean ± SEM; n = 5; a = compared to Vehicle (Distilled water, 10ml/kg): 1p< 0.05; 2p<0.01, 
3p<0.001; PCV0 = pre-treatment value on day 0, PCV4 = post-treatment value on day four, CQ = chloroquine, PL, 
crude extract of P. linearifolia. Numbers refer to dose in mg/kg. 
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PCV reduction was significantly attenuated by 400 mg/kg chloroform fraction (p<0.01). Also 200 and 400g 
mg/kg of the aqueous fraction showed a significant effect in preventing PCV (p<0.05 for both doses); but the 
effect was lower than the standard drug chloroquine 25 mg/kg (p<0.001). On the other hand, 100 and 200 
mg/kg of the chloroform fraction, 100 mg/kg aqueous fraction and all doses of the ethyl acetate fraction failed 
to prevent the reduction in packed cell volume significantly (Figure 5). Similarly, within group analysis 
indicated all fractions failed to prevent PCV reduction after treatment except chloroquine 25 mg/kg which 
prevented significant PCV change after treatment. 
 
Figure 5. Packed cell volume of infected animals treated with solvent fractions of P. linearifolia in the 4 day 
suppressive test. Data are expressed as mean ± SEM; n = 5; a = compared to vehicle (2% Tween 80 10 ml/kg): 1p< 
0.05; 2p<0.01, 3p<0.001; PCV0 = pre-treatment value on day 0, PCV4 = post-treatment value on day four, CF = 
Chloroform fraction, CQ = chloroquine, EF, Ethyl acetate fraction, AF, aqueous fraction. Numbers refer to dose in 
mg/kg.  
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4.4.5. Rane’s test of the crude extract 
On this antimalarial activity test on established (late) infection only 600 mg/kg of the crude extract of P. 
linearifolia revealed a significant parasite level reduction (p<0.01) compared to vehicle treated mice (Table 
4). The standard drug chloroquine 25 mg/kg showed a highly significant parasite level reduction (p<0.001) 
which cured all mice at day seven. Both 200 and 400 mg/kg of the crude extract failed to reduce parasitemia 
level significantly as compared to vehicle treated mice. Survival time was not altered by all doses of the crude 
extract. However, the standard drug chloroquine 25 mg/kg significantly prolonged survival time of the mice 
as compared to vehicle treated mice (p<0.001). Between different doses comparison analysis showed that 600 
mg/kg prevented parasitemia level significantly higher than 400 mg/kg (Table 4). 
4.5.6. Rane’s test of the aqueous fraction  
The fraction with the highest antimalarial activity (aqueous fraction) in the four day suppressive test was 
further evaluated for its effect on established parasite infection. In this case only 400 mg/kg of the aqueous 
fraction exhibited a statistically significant parasite level reduction (p<0.01) as compared to vehicle treated 
mice. On the other hand, chloroquine 25 mg/kg cured all mice on day 7 and the reduction in parasitaemia was 
significantly higher (p<0.001) when compared to vehicle treated mice as well as all doses of the fraction. Only 
400 mg/kg of the aqueous fraction significantly prolonged survival time of mice compared to vehicle treated 
mice (p<0.05) (Table 4). Comparison analysis between the group showed 400 mg/kg of the aqueous fraction’s 
effect in parasitemia level reduction was significantly higher than 100 and 200 mg/kg (p<0.05) (Table 4). 
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Table 4. Parasitaemia and survival time of infected animals treated with crude extract and aqueous fraction of 
P. linearifolia in the Rane’s test 
 
Dose 
                                    Parasitemia level  
%Inhibition 
 
Survival Time Day3 Day4 Day5 Day6 Day7 
PL200  10.08±2.06 28.74±5.56 49.36±5.90 53.99±5.74 61.25±8.87b3 22.22±11.26 8.40±0.50b3 
PL400  11.01±1.80 34.01±3.90 47.60±2.01 56.47±3.52 64.28±2.66b3 18.37±3.38 8.80±0.66b3 
PL600  8.64±1.41 25.02±4.43 36.01±4.22 38.75±3.58 41.89±2.77a3,b3,c1 46.79±3.52 10.40±1.36b3 
AF100  11.26±1.62 25.30±4.16 39.66±3.78 53.36±2.60 69.93±2.70b3 11.18±3.42 9.00±0.70b3 
AF200 9.01±1.49 26.28±3.87 40.42±2.47 55.12±2.39 69.84±2.05b3 11.30±2.60 9.60±0.81b3 
AF400  8.87±1.92 12.47±3.24 21.92±6.79 27.14±9.16 39.86±11.62a2,b2,d1,e1 49.37±14.76 12.00±1.51a1,b3 
CON. 11.52±1.86 37.39±5.74 61.62±6.87 66.96±5.70 78.75±5.60            - 7.60±0.24 
CQ25 9.56±3.04 9.41±3.71 1.10±0.40 0.32±0.23 0.00±0.00a3 100.00±0.00 30.00±0.00 a3 
Data are expressed as mean ± SEM; n = 5: a, compared to negative control (Distilled water); b to CQ; c to PL400; d to 
AF100; e to AF200:  1p<0.05, 2p<0.01, 3p<0.001; AF = Aqueous fraction, CQ = chloroquine, EF, ethyl acetate 
fraction, AF, aqueous fraction, CON = Negative control, PL, crude extract of P. linearifolia. Numbers refer to dose in 
mg/kg. 
4.4.7. Effect of crude extract and aqueous fraction on the body weight and rectal temperature in the 
Rane’s test 
Rectal temperature analysis indicated that 400 and 600 mg/kg of P. linearifolia had a significant preventive 
effect on the reduction in rectal temperature compared to vehicle treated mice (p<0.05). The effect of 
chloroquine 25 mg/kg on prevention of rectal temperature reduction was much higher than the extract 
(p<0.001) (Table 5). Weight reduction was not significantly prevented by all doses of the crude extract. 
However, chloroquine 25 mg/kg significantly averted weight reduction as compared to vehicle treated mice 
(p<0.01) (Table 5). 
Analysis of rectal temperature change of mice within groups showed that all doses of the crude extract failed 
to prevent any significant rectal temperature change after treatment. But, the standard drug chloroquine 25 
mg/kg averted a significant temperature change after treatment. All doses of the crude extract failed to prevent 
weight change after treatment except the standard drug chloroquine 25 mg/kg.  
On the other hand, only 400 mg/kg of the fraction significantly prevented the reduction in the temperature 
compared to vehicle treated mice (p<0.05). However, its effect was much lower than chloroquine 25 mg/kg 
(p<0.001). Chloroquine 25 mg/kg halted temperature dropping significantly compared to all doses of the 
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fraction (p<0.05). Only 400 mg/kg of the aqueous fraction prevented body weight loss significantly as 
compared to vehicle treated mice (p<0.05). The other doses of the fraction failed to attenuate body weight 
reduction significantly (Table 5). 
Analysis of rectal temperature change of mice within groups showed that all doses of the aqueous fraction 
failed to prevent a significant rectal temperature change after treatment. Only the standard drug chloroquine 
25 mg/kg averted significant rectal temperature reduction. Also, mice administered with 400 mg/kg of the 
aqueous fraction did not show any significant weight change after treatment.  
Table 5. Body weight and rectal temperature change of infected mice treated with crude extract and solvent 
fraction of P. linearifolia in the Rane’s test 
 
Dose 
               Weight                      Temperature 
      W0 W4 % Change    T0 T4 % Change 
PL200 27.90±1.08 24.74±0.80 -11.32b2 36.98±0.17 34±0.46 -7.67b2 
PL400 27.08±1.00 23.68±0.89 -12.55b2 36.64±0.12 34.32±0.35 -6.33a1,b1 
PL600 26.92±1.29 24.62±0.79 -8.54b1 37.12±0.11 34.52±0.43 -7.00a1,b2 
AF100 27.98±0.95 26.32±1.10 -5.93 37.62±0.13 33.40±0.14 -11.21b3 
AF200 28.16±1.84 26.38±1.60 -6.32 37.18±0.26 34.20±0.35 -8.01b2 
AF400 29.12±0.99 28.24±1.36 -3.02a1 37.86±0.14 35.94±0.47 -5.07 a1,c2 
CON. 27.26±1.13 23.64±1.27 -13.27 36.74±0.21 32.44±0.20 -11.70 
CQ25 26.08±1.20 26.56±1.39 1.9a2 36.64±0.17 36.22±0.24 -1.14a3 
Data are expressed as mean ± SEM; n = 5: a, compared to control; b to CQ; c to AF100: 1p<0.05, 2p<0.01, 3p<0.001; 
AF = Aqueous fraction, CQ = chloroquine, EF, ethyl acetate fraction, AF, aqueous fraction, CON = Control, PL, crude 
extract of P. linearifolia. Numbers refer to dose in mg/kg. 
4.4.8. Effect of crude extract and aqueous fraction on packed cell volume in the Rane’s test 
Only 600 mg/kg of the crude extract had significantly prevented PCV reduction as compared to vehicle 
treated mice (p<0.05) (Figure 6). Within group analysis showed both chloroquine 25 mg/kg and all doses of 
the crude extract were unable to prevent any significant PCV change after treatment. 
All doses of the aqueous fraction failed to prevent PCV reduction significantly. However, the standard drug 
chloroquine 25 mg/kg averted PCV reduction significantly as compared to vehicle treated mice (p<0.01). On 
the other hand, within group analysis indicated that neither the fraction nor the standard drug prevented a 
significant PCV change after treatment (Figure 6). 
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Figure 6. Packed cell volume of infected animals treated with crude extract and solvent fraction of P. 
linearifolia in the Rane’s test 
Figure 6. Packed cell volume of infected animals treated with crude extract and solvent fraction of P. linearifolia in the 
Rane’s test. Data are expressed as mean ± SEM; n = 5: a, compared to control; b, to 600 mg/kg; c, to CQ 25; d, to 400 
mg/kg; e, to 200 mg/kg: 1p<0.05, 2p<0.01, 3p<0.001; AF = Aqueous fraction, CQ = chloroquine, EF, ethyl acetate 
fraction, AF, aqueous fraction, CON = Control, PL, crude extract of P. linearifolia. Numbers refer to dose in mg/kg. 
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5. DISCUSSION 
The in vivo model was preferred for this study because it takes into account the possible prodrug effect and 
possible involvement of the immune system in eradication of infection (103). P. berghei provides a 
well‑established experimental model of malaria infection (104), producing pathological symptoms which 
closely mimic those of human malaria (105). Even though the rodent malaria model is not exactly similar to 
that of the human Plasmodium parasites, it is the first step to screen most of the in vivo antimalarial activities 
of test compounds (97, 101).  
In addition, several of the currently available antimalarial agents such as chloroquine, halofantrine, 
mefloquine and artemisinin derivatives have been identified using rodent model of malaria (106). The 4 day 
suppressive test, which mainly evaluates the antimalarial activity of candidates on early infections, and Rane’s 
test, which evaluates the curative capability of candidate extracts on established infections, are commonly 
used for antimalarial drug screening. In both methods, determination of percent inhibition of parasitemia is the 
most reliable parameter (97, 101, 102).   
It can be clearly seen from the results that percentage parasitemia measured in the 4 day suppressive test was 
reduced dose dependently by the crude extract in P. berghei infected mice, pointing to the fact that the plant is 
endowed with antimalarial activity. Alkaloids and terpenoids present in the extract might be responsible for 
their antimalarial activity. The alkaloids are known to possess antiplasmodial properties, the most famous 
being quinine (107). Survival time was significantly prolonged by the crude extract and aqueous fraction 
which is related with reduction of parasitemia level.  
Among the fractions, the aqueous fraction was found to possess higher antimalarial activity than the 
chloroform and ethyl acetate fractions. Hence in this study the hydroalcoholic extract and aqueous fraction 
showed higher antiplasmodial activity than the chloroform and ethyl acetate fractions. The observed activities 
of the hydrophilic extracts are in contrast to those reported by Jenett Siems et al., who found that lipophilic 
extracts were more active than hydrophilic extracts (108). Hydrophilic extracts are closer in composition to 
the aqueous preparations commonly used by traditional practitioners. Francois et al. have similarly 
investigated the organic extracts from the roots, stem bark, fruit rind, seeds and leaves of plants and found a 
wide range of activities with the highest activities being found in the methylene chloride root extracts (109). 
Methanolic and chloroform extract of P. linearifolia is reported to possess in vitro antiplasmodial activity 
(92). Therefore, the present in vivo study is consistent with the previous in vitro findings. 
Different ethnobotanical studies indicated that from the sub family Periplocoideae (Apocynaceae), where P. 
linearifolia belonged, many plant species are used for the treatment of malaria. Similarly, phytochemical 
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analysis studies showed these plants contain different alkaloids and terpenoids which had a promising 
antiplasmodial activities in in vitro studies (80-85). Moreover, many chemical compounds have been isolated 
and identified from species of the Periploca genus, such as α- and β-amyrin, lupeol and β-sitosterol from 
Periploca laevigata (86). Moreover, several lupene-type triterpenes and elemane-type sesquiterpenes have 
been isolated from Periploca aphylla and roots of P. laevigata respectively (86, 87). Lupeol, β-amyrin and β-
sitosterol (terpenoids), inhibited both chloroquine sensitive and resistant strains of P. falciparum in in vitro 
studies (88). Therefore, the antiplasmodial activity of P. linearifolia in the present in vivo study is in 
agreement with other plants belonging to the same sub family and genus. 
 The methanol extracts of the root bark of P. linearifolia showed anti-oxidant activity dependent on 
concentration. Three compounds namely, Lupeol, β- sitosterol and β- amyrin were isolated from the root bark 
of P. linearifolia. The three compounds belonged to the terpenoid class of compounds inhibited both 
chloroquine sensitive and chloroquine resistant strains of P. falciparum (88). Similarly, the present in vivo 
study is consistent with the above finding. 
Anemia, body weight loss and body temperature reduction are the general features of malaria infected mice 
(110). PCV was measured to evaluate the effectiveness of the crude extract and fractions in preventing 
hemolysis due to escalating parasitemia level. The underlying cause of anemia includes the following 
mechanisms; the clearance and/or destruction of infected RBCs, the clearance of uninfected RBCs, and 
erythropoietic suppression and dyserythropoiesis. Each of these mechanisms has been implicated in both 
human and mouse malarial anemia (111). This necessitates hematocrit (packed cell volume) analysis that 
evaluates the effectiveness of the extract in preventing hemolysis. In the four day suppressive test 200 mg/kg 
of the aqueous extract, 400 mg/kg of the crude extract, chloroform and aqueous fractions and 600 mg/kg of 
the crude extract prevented PCV reduction significantly. In addition, in the Rane’s test 600 mg/kg was able to 
avert significant PCV reduction. This reversal of PCV reduction by the crude extract and fractions may be 
related with parasitemia level reduction with the extract and fractions. 
The crude extract and most doses of the fractions failed to prevent significantly the reduction in body weight. 
This phenomenon in decrement of body weight may be due to disturbed metabolic function and 
hypoglycaemia that has been reported to be associated with malaria infection (112).  
Rectal temperature measurement showed that the mice developed hypothermia particularly in the late 
infection (Rane’s test) with P. berghei parasites. Fever is one of the symptoms of human malaria. In contrast, 
this model of malaria was associated with hypothermia rather than pyrexia. In the curative test, the infected 
mice developed profound hypothermia with rectal temperature falling by as much as 5°C. The prolonged 
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development of hypothermia in mice can be attributed to the general debilitating effects of malaria on the 
host, which results in the loss of body heat and eventual death. The absence of pyrogenic response in this 
model is that small animals like mice have a large surface area-to-body mass ratio, which resulted in a higher 
degree of heat loss and prevents the development of fever caused by pyrogenic agents (113).  
Malaria parasites also affect host carbohydrate, lipid and protein metabolism (114, 115). A decrease in the 
metabolic rate of infected mice occurred just before death and was accompanied by a corresponding decrease 
in internal body temperate (116). Therefore, effective antimalarial agents are expected to prevent the 
reduction in rectal temperature. As a result, the crude extract and fractions were able to significantly attenuate 
the reduction in rectal temperature as compared to vehicle treated mice. 
 
In the curative test, blood samples were taken and smears prepared daily to evaluate the curative ability of the 
extract. As indicated in the results section, 600 mg/kg of the crude extract brought about reduction of 
parasitemia after second dose. However, 400 mg/kg of the aqueous fraction and the standard drug chloroquine 
25 mg/kg started parasitemia reduction activity right after the first dose. This delay of activity of 600 mg/kg of 
the crude extract may be indicative of the need for a loading dose or the extract might have a delayed onset of 
action. Generally, the results obtained from the Rane’s test suggest that 600 mg/kg of the crude extract and 
400 mg/kg of the aqueous fraction have therapeutic efficacy against established malaria parasite. This 
property is additive to the suppressive activity and it may be possible to consider the plant as a potential 
source of antimalarial agents (117). 
Although the active compound is yet to be identified, the antimalarial activity of P. linearifolia could be 
attributed to a single or a combination of its secondary metabolites such as alkaloids, terpenoids and phenolic 
compounds. These metabolites have been reported to have different extent of antimalarial activity in the 
literature (118-120).  
Anti-malarial test materials with more than 30% suppressive effect on the level of parasitaemia (121, 122) or 
that can prolong the survival date of treated mice (123) compared to the control group are often considered 
effective in standard screening tests. Therefore, the present in vivo antimalarial activity test denotes P. 
linearifolia is effective in both the four day suppressive test and curative test models. 
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6. CONCLUSION 
From the results of this study it can be concluded that the plant extract is relatively safe to mice. The present 
study indicates that 80% methanolic extract and solvent fractions of P. linearifolia have a promising 
antiplasmodial activity, with varying degree and/or differential effect on the measured parameters. The crude 
extract appeared to be superior in suppressing parasitemia and where 400 mg/kg and 600 mg/kg protected 
infected mice from parasite-induced PCV reduction. Moreover, 400 mg/kg of the chloroform fraction and 200 
mg/kg and 400 mg/kg of the aqueous fraction protected PCV reduction and displayed greater parasite 
suppression among the fractions. The results reported in this study illustrate that correlations exist between the 
traditional use and the earlier in vitro findings. 
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7. RECOMMENDATION 
From the present study, the following works are suggested for further investigation on the plant:  
 Active compounds, responsible for the antimalarial activity,  have to be isolated  
  Mechanism of antimalarial action of the compounds has to be studied in detail.  
 Sub-acute and chronic toxicity study in higher animals has to be conducted to know the safety of P. 
linearifolia stem bark. 
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